There are several methods published on indirectly activating PP2A as an anti-cancer treatment, such as antagonizing the endogenous PP2A inhibitors SET (via OP449 [41,157] or FTY720 [158,159]), and CIP2A (via bortezomib, erlotinib, or celastrol) or disrupting PP2A post translational modifications [143]. This evidence concerns the gene PTPA and cancer.